ABT vs DXCM vs TMO Stock Comparison

Abbott Laboratories, Dexcom and Thermo Fisher Scientific Prices as of Nov 13, 2026 Peers: Industry group
ABT Abbott Laboratories
$108.54 +5.4% 1M -16.0% 1Y
Market cap
$187.81B
P/E
40.0x
Revenue (TTM)
$48.23B
Div. yield
0.02%
Medical Devices Healthcare
3 wins
DXCM Dexcom Inc
$83.33 -0.2% 1M +39.5% 1Y
Market cap
$30.71B
P/E
31.0x
Revenue (TTM)
$5.10B
Div. yield
–
Medical Devices Healthcare
7 wins

Head to Head

12 decided of 12

Dexcom leads on 7 of the 12 questions below (Dexcom 7, Abbott Laboratories 3, Thermo Fisher Scientific 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionABTDXCMTMOLeader
Larger companyMarket capitalisation $187.81B $30.71B $257.22B TMO
Cheaper on earningsLower P/E, profitable companies only 40.0x 31.0x 36.4x DXCM
Cheaper on forward earningsLower price / next fiscal year consensus EPS 19.1x 29.1x 27.0x ABT
Faster revenue growthRevenue growth, trailing twelve months +10.0% +13.0% +8.3% DXCM
More profitableNet margin, trailing twelve months 9.7% 19.4% 14.9% DXCM
Better return on capitalReturn on invested capital 5.7% 32.4% 8.0% DXCM
Less leveragedLower net debt / EBITDA 2.5x -0.9x 3.1x DXCM
Higher dividend yieldTrailing dividend yield 0.02% 0.00% 0.00% ABT
Better 1-year returnPrice return, last 12 months -16.0% +39.5% +20.7% DXCM
Better 5-year returnAnnualised price return, 5 years -3.3%/yr -12.4%/yr +2.0%/yr TMO
Less volatileAnnualised volatility, 1 year 28.5% 37.9% 30.7% ABT
Higher overall scoreMean of the five percentile scores vs peers 56/100 80/100 60/100 DXCM

Percentile Scorecard

ABTDXCMTMO

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisABTDXCMTMO
Valuation 74 #65 of 243 67 #82 of 243 62 #94 of 243
Growth 26 #168 of 228 83 #40 of 228 41 #136 of 228
Profitability 82 #41 of 222 100 #1 of 222 82 #40 of 222
Financial Health 33 #167 of 248 59 #103 of 248 31 #172 of 248
Shareholder Returns 65 #56 of 158 91 #15 of 158 82 #29 of 158
Overall 56 80 60
  • ABT ranked among 252 companies in Medical Devices and Diagnostics
  • DXCM ranked among 252 companies in Medical Devices and Diagnostics
  • TMO ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodABTDXCMTMOSPY
1 month +5.4%-0.2%+4.0% -2.0%
3 months -2.4%-7.2%+19.1% -2.8%
6 months +28.5%+35.2%+59.7% +2.0%
Year to date -13.4%+25.6%+20.8% +10.6%
1 year -16.0%+39.5%+20.7% +12.2%
3 years +11.8%-17.8%+52.5% +68.1%
3 years, per year +3.8%-6.3%+15.1% +18.9%
5 years -15.5%-48.4%+10.2% +61.4%
5 years, per year -3.3%-12.4%+2.0% +10.1%
10 years +170.4%+411.2%+362.9% +248.5%
10 years, per year +10.5%+17.7%+16.6% +13.3%

Risk

MeasureABTDXCMTMOSPY
Volatility, 1Y 28.5%37.9%30.7% 13.6%
Downside volatility, 1Y 27.8%34.3%29.2% 13.9%
Beta vs S&P 500, 1Y 0.070.720.71 1.00
Return / volatility, 1Y -0.561.040.67 0.90
Max drawdown, 5Y -41.6%-66.3%-41.5% -25.4%
From 52-week high -16.9%-9.8%-3.0% -3.2%
52-week high $130.59$92.34$721.63 $779.14
52-week low $82.56$57.56$438.34 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleABTDXCMTMO
P/E now vs peer median 40.0xmedian 26.5x 31.5xmedian 26.5x 36.6xmedian 26.5x
P/S now vs peer median 3.9xmedian 2.7x 6.1xmedian 2.7x 5.5xmedian 2.7x
EV/EBITDA now vs peer median 20.3xmedian 18.4x 19.7xmedian 18.4x 25.5xmedian 18.4x
P/FCF now vs peer median 27.8xmedian 25.4x 28.3xmedian 25.4x 34.2xmedian 25.4x
P/B now vs peer median 3.6xmedian 2.5x 12.3xmedian 2.5x 4.7xmedian 2.5x
PEG now vs peer median -13.92median 0.98 0.73median 0.98 4.84median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsABTDXCMTMO
Revenue $48.23B $5.10B $47.35B
Gross profit $27.46B $3.24B $19.45B
Operating income $6.65B $1.22B $8.47B
Net income $4.70B $991.00M $7.09B
Free cash flow $6.76B $1.10B $7.60B
R&D $3.31B $608.10M $1.40B
EPS (diluted) $2.70 $2.58 $19.06
Cash & equivalents $4.05B $961.40M $5.46B
Total debt $31.16B $389.80M $41.37B
Shares (diluted) 1.74B 383.50M 371.00M
Enterprise value $161.67B $22.53B $233.73B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricABTDXCMTMO
P/E 40.0x 31.5x 36.6x
P/FCF 27.8x 28.3x 34.2x
P/Operating cash flow 21.2x 22.0x 27.8x
P/S 3.9x 6.1x 5.5x
P/B 3.6x 12.3x 4.7x
P/Tangible book 5.9x 12.7x 7.1x
EV/EBITDA 20.3x 19.7x 25.5x
EV/EBIT 32.3x 24.2x 34.8x
EV/Revenue 4.5x 5.8x 6.2x
EV/FCF 31.8x 27.0x 38.8x
EV/Operating cash flow 24.3x 21.0x 31.6x
PEG (3Y EPS CAGR) -13.92 0.73 4.84

Growth

14 metrics
MetricABTDXCMTMO
Revenue growth (1Y) 10.0% 13.0% 8.3%
Revenue CAGR (3Y) 6.5% 14.5% 2.9%
Gross profit growth (1Y) 12.1% 21.5% 7.8%
Gross profit CAGR (3Y) 7.8% 14.2% 4.0%
Operating income growth (1Y) -13.8% 57.4% 12.8%
Operating income CAGR (3Y) 3.5% 34.2% 7.2%
Net income growth (1Y) -66.4% 37.5% 7.9%
Net income CAGR (3Y) -3.1% 38.0% 6.2%
EPS growth (1Y) -66.1% 46.1% 9.7%
EPS CAGR (3Y) -2.9% 43.0% 7.6%
Operating cash flow growth (1Y) -2.9% -2.3% 21.9%
Operating cash flow CAGR (3Y) 10.6% 23.7% 4.5%
Free cash flow growth (1Y) -2.3% 3.4% 24.3%
Free cash flow CAGR (3Y) 14.6% 30.0% 5.1%

Profitability

14 metrics
MetricABTDXCMTMO
Gross margin 56.9% 63.4% 41.1%
EBITDA margin 21.9% 29.5% 24.4%
Operating margin 13.8% 24.0% 17.9%
Pretax margin 13.6% 24.7% 16.7%
Net margin 9.7% 19.4% 14.9%
FCF margin 14.0% 21.5% 16.0%
Operating cash flow margin 18.4% 27.7% 19.7%
Return on equity 9.1% 38.4% 13.2%
Return on assets 4.3% 15.6% 6.2%
Return on invested capital 5.7% 32.4% 8.0%
Return on capital employed 7.2% 29.9% 8.5%
Asset turnover 0.4x 0.8x 0.4x
Cash conversion (OCF / net income) 1.9x 1.4x 1.3x
Stock comp / revenue 1.5% 3.0% 0.7%

Financial Health

11 metrics
MetricABTDXCMTMO
Debt / assets 28.8% 6.2% 36.2%
Debt / equity 0.6x 0.2x 0.8x
Net debt / EBITDA 2.5x -0.9x 3.1x
Debt / FCF 4.6x 0.4x 5.4x
Liabilities / assets 52.3% 59.4% 52.1%
Equity / assets 47.7% 40.6% 47.9%
Interest coverage 6.7x – 12.0x
Current ratio 1.5x 1.7x 1.8x
Quick ratio 0.8x 1.3x 1.2x
Cash ratio 0.3x 0.8x 0.4x
Altman Z-score 3.36 7.53 4.18

Shareholder Returns

7 metrics
MetricABTDXCMTMO
Dividend yield 2.3% – 0.3%
Net buyback yield 0.7% 2.2% 1.6%
Shareholder yield 3.0% 2.2% 1.8%
Payout ratio (earnings) 92.0% – 9.5%
Payout ratio (FCF) 64.0% – 8.9%
Dividend growth (1Y) 6.9% – 8.0%
Dividend CAGR (3Y) 7.4% – 10.1%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusABTDXCMTMO
Forward P/E 19.1xFY2026 29.1xFY2026 27.0xFY2026
EPS, next fiscal year $5.69FY2026 $2.86FY2026 $25.92FY2026
EPS growth, next FY +10.5%FY2026 +36.8%FY2026 +13.3%FY2026
EPS growth, the year after +10.2% +4.2% +2.2%
Revenue, next fiscal year $52.99BFY2026 $5.08BFY2026 $50.12BFY2026
Revenue growth, next FY +19.5%FY2026 +9.0%FY2026 +12.5%FY2026
Revenue growth, the year after -2.3% +16.0% -2.7%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersABTDXCMTMO
Held by institutions 79.2% 100.0% 90.2%
Institutions holding 2,983 977 2,627
Change in shares held, QoQ +0.3% +6.3% +0.8%
Institutions buying 1,261 521 1,145
Institutions selling 1,379 345 1,145
Buyers to sellers 0.91 1.51 1.00

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ABTDXCMTMO
ABT 1.00 0.36 0.24
DXCM 0.36 1.00 0.26
TMO 0.24 0.26 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ABT, DXCM and TMO?

Thermo Fisher Scientific (TMO) is the largest by market capitalisation: Abbott Laboratories (ABT) $187.81B, Dexcom (DXCM) $30.71B, Thermo Fisher Scientific (TMO) $257.22B.

Which stock is cheaper, ABT, DXCM and TMO?

Dexcom (DXCM) trades on the lowest price-to-earnings ratio (Abbott Laboratories (ABT) 40.0x, Dexcom (DXCM) 31.0x, Thermo Fisher Scientific (TMO) 36.4x). On next year's consensus earnings, Abbott Laboratories (ABT) is cheapest (Abbott Laboratories (ABT) 19.1x, Dexcom (DXCM) 29.1x, Thermo Fisher Scientific (TMO) 27.0x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Dexcom (DXCM) grew revenue fastest over the trailing twelve months: Abbott Laboratories (ABT) +10.0%, Dexcom (DXCM) +13.0%, Thermo Fisher Scientific (TMO) +8.3%.

Which company is more profitable?

Dexcom (DXCM) has the highest net margin (Abbott Laboratories (ABT) 9.7%, Dexcom (DXCM) 19.4%, Thermo Fisher Scientific (TMO) 14.9%). On return on invested capital, Dexcom (DXCM) leads (Abbott Laboratories (ABT) 5.7%, Dexcom (DXCM) 32.4%, Thermo Fisher Scientific (TMO) 8.0%).

Which stock has performed better?

Over the past year Dexcom (DXCM) returned the most: Abbott Laboratories (ABT) -16.0%, Dexcom (DXCM) +39.5%, Thermo Fisher Scientific (TMO) +20.7%. Over five years, Thermo Fisher Scientific (TMO) compounded fastest (Abbott Laboratories (ABT) -3.3%/yr, Dexcom (DXCM) -12.4%/yr, Thermo Fisher Scientific (TMO) +2.0%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Abbott Laboratories (ABT) has the highest dividend yield: Abbott Laboratories (ABT) 0.02%, Dexcom (DXCM) 0.00%, Thermo Fisher Scientific (TMO) 0.00%. Dexcom (DXCM) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Abbott Laboratories (ABT) has been the steadiest (Abbott Laboratories (ABT) 28.5%, Dexcom (DXCM) 37.9%, Thermo Fisher Scientific (TMO) 30.7%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ABT, DXCM and TMO?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Dexcom (DXCM) leads on 7. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.